-
公开(公告)号:US20020037934A1
公开(公告)日:2002-03-28
申请号:US09925970
申请日:2001-08-10
发明人: Ashok Amin , Steven Abramson
IPC分类号: A61K039/395 , C12Q001/70 , A61K039/40 , A61K039/42 , A61K039/29 , C12N005/06 , C12N005/16 , A01N025/00
CPC分类号: C07K16/241 , A61K2039/505 , C07K2317/24
摘要: Hepatitis can be treated by administering to a patient in need thereof an effective amount of a compound that neutralizes the effects of secreted TNFalpha. Two types of these compounds are extracellular ligand binding proteins of the human p75 TNF receptor, such as etanercept (Enbrel), and humanized monoclonal antibodies that neutralize the activity of TNFalpha, such as inflixamab (Remicade).
摘要翻译: 可以通过向有需要的患者施用有效量的中和分泌的TNFα的作用的化合物来治疗肝炎。 两种类型的这些化合物是人p75 TNF受体的细胞外配体结合蛋白,如依那西普(Enbrel)和中和TNFα活性的人源化单克隆抗体,如英夫利昔单抗(Remicade)。